Runs a 450-bed NABH-accredited multi-specialty hospital in Trichy, Tamil Nadu, under the Kauvery Hospital group.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 34 | 47 | 70 | 97 | 127 | 148 | 166 | 194 |
| Borrowings | 9 | 29 | 29 | 50 | 82 | 89 | 86 | 84 |
| Other Liabilities | 11 | 13 | 13 | 18 | 38 | 32 | 31 | 38 |
| Total Liabilities | 70 | 105 | 129 | 182 | 264 | 286 | 300 | 332 |
| AssetsFixed Assets | 39 | 74 | 75 | 84 | 206 | 248 | 245 | 248 |
| CWIP | 0 | 2 | 6 | 34 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 31 | 29 | 48 | 63 | 57 | 38 | 55 | 84 |
| Total Assets | 70 | 105 | 129 | 182 | 264 | 286 | 300 | 332 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 16 | 11 | 26 | 29 | 32 | 38 | 58 | 79 |
| Cash from Investing | -9 | -8 | -43 | -29 | -48 | -56 | -51 | -17 |
| Cash from Financing | -5 | -4 | 18 | -1 | 16 | 20 | -2 | -21 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 13 | 7 | -15 | 16 | -12 | -37 | -6 | 63 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (44.0×) and current (40.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 22.5% growth and a 40× exit, ₹115 only delivers your return if you pay ₹144. The price is currently baking in 18% growth.
EPS grows 22.5%/yr for 5 years, then fades to 6% over 2, exits at 40×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 22.5% | 3.50 |
| FY28 | 22.5% | 4.29 |
| FY29 | 22.5% | 5.26 |
| FY30 | 22.5% | 6.44 |
| FY31 | 22.5% | 7.89 |
| FY32 | 14.3% ·fade | 9.01 |
| FY33 | 6.0% ·fade | 9.55 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.